| 摘要 |
Compositions of the polypeptide EEIIMI, Ac-RMAPEEIMDRPFLYVVR-amide, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prologing the half lives of the fibrinolytic agents. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide EEIIMI and/or Ac-RMAPEEIIMDRPFLYVVR-amide and one or more currently used plasminogen activators. |
